High Dimensional Analysis of Immune Cells in Pediatric Patients
Trial Parameters
Brief Summary
The purpose of this study is to characterize immune cells using single-cell transcriptomic analysis in pediatric patients aged 2 to 18 years undergoing general anesthesia who are expected to receive Rocuronium, a non-depolarizing neuromuscular blocking agent, in the event of an allergic reaction.
Eligibility Criteria
Inclusion Criteria: * Pediatric patients between the ages of 2 and 18 undergoing general anesthesia and surgery using the neuromuscular blocker, rocuronium. Exclusion Criteria: * Patients who have received immunomodulators, immunosuppressants, etc. * Patients with autoimmune diseases (rheumatoid arthritis, lupus, Behcet's disease, etc.) * Patients who regularly take, or have taken within 4 weeks, medications that may affect the immune system (oral steroids, anti-inflammatories, etc.) * Other cases where the Principal Investigator determines that it is difficult to conduct the study.